Author

D. Currier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:genetic perturbation / CRISPR· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

T. Chen· 3 shared H.-M. Lee· 2 shared J. Easton· 2 shared J. Fang· 2 shared J. Low· 2 shared J. Yang· 2 shared M. Pan· 2 shared P. Geeleher· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

M. Pan, Y. Zhang, W. C. Wright, X. Liu, B. Passaia, D. Currier, R. H. Chapple, J. Steele, J. P. Connelly, M. Lu, H.-M. Lee, A. Loughran, L. Yang, B. J. Abraham, S. M. Pruett-Miller, , P. Geeleher

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

bioRxiv · May 9, 2024Cancer Biology

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1

A. Abu-Zaid, S. Singh, W. LIN, J. Low, A. Abdolvahabi, B. Bailey Cooke, J. Bowling, S. Vaithiyalingam, J. Fang, D. Currier, M.-K. Yun, A. AlTahan, D. Fernando, J. Maier, H. Tillman, , J. YANG

This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.

bioRxiv · Dec 11, 2019 · PreprintCancer Biology